EnteraSense

The company’s lead product, the PillSense capsule system, has demonstrated feasibility and safety in first-in-human trials for rapid detection of upper GI bleeding. In a published study with healthy volunteers simulating UGIB conditions, the capsule accurately detected blood presence without adverse events. The device enables real-time wireless monitoring for up to three days and has received FDA approval for clinical use[6].

The technology aims to reduce unnecessary endoscopies and improve triage in emergency settings.

Marketed as the first and only FDA-approved capsule for this indication.

No major adverse events reported in initial human studies; high tolerability observed[6].

Commercial launch status confirmed; ongoing commercialization efforts targeting US/EU markets[5].